Lost in translation: CRF1 receptor antagonists and addiction treatment

Neuropsychopharmacology

Volumn 41, Issue 12, 2016, Pages 2795-2797

  Shaham, Yavin ^a   De Wit, Harriet ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; PEXACERFONT; VERUCERFONT; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR;

ADDICTION; ALCOHOLISM; COCAINE DEPENDENCE; CRAVING; DEPRESSION; DRUG CRAVING; DRUG EFFICACY; HEROIN DEPENDENCE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NONHUMAN; NOTE; PRIORITY JOURNAL; STRESS; TOBACCO DEPENDENCE; ANTAGONISTS AND INHIBITORS;

BEHAVIOR, ADDICTIVE; CORTICOTROPIN-RELEASING HORMONE; HUMANS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE;

EID: 84991106881     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2016.94     Document Type: Note

References (19)

1. Bale TL, Vale WW. (2004). CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 44: 525-557
2. Cole BJ, Cador M, Stinus L, Rivier J, Vale W, Koob GF. (1990). Central administration of a CRF antagonist blocks the development of stress-induced behavioral sensitization. Brain Res 512: 343-346
3. Fleck BA, Hoare SR, Pick RR, Bradbury MJ, Grigoriadis DE. (2012). Binding kinetics redefine the antagonist pharmacology of the corticotropin-releasing factor type 1 receptor. J Pharmacol Exp Ther 341: 518-531
4. Grillon C, Hale E, Lieberman L, Davis A, Pine DS, Ernst M. (2015). The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle. Neuropsychopharmacology 40: 1064-1071
5. Heilig M, Epstein DE, Nader M, Shaham Y. (2016). It is time to connect: addiction neuroscience and social context. Nat Rev Neurosci. Holsboer F, Ising M. (2008). Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 583: 350-357
6. Koob GF. (2010). The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314: 3-14
7. Koob GF, Bloom FE. (1985). Corticotropin-releasing factor and behavior. Fed Proc 44(1 Pt 2): 259-263
8. Kwako LE, Spagnolo PA, Schwandt ML, Thorsell A, George DT, Momenan R., et al. (2015). The corticotropin releasing hormone-1 (CRH1) receptor antagonist pexacerfont in alcohol dependence: a randomized controlled experimental medicine study. Neuropsychopharmacology 40: 1053-1063
9. Mantsch JR, Baker DA, Funk D, Le AD, Shaham Y. (2016). Stressinduced reinstatement of drug seeking: 20 years of progress. Neuropsychopharmacology 41: 335-356
10. Meyer RE, Mirin SM. (1979). The Heroin Stimulus: Implications for a Theory of Addiction. Plenum Medical Book Company: New York
11. Schulz DW, Mansbach RS, Sprouse J, Braselton JP, Collins J, Corman M., et al. (1996). CP-154, 526: a otent nd selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc Natl Acad Sci U S A 93: 10477-10482
12. Schwandt ML, Cortes CR, Kwako LE, George DT, Momenan R, Sinha R., et al. (2016). The CRF1 antagonist verucerfont in anxious alcohol dependent women: Translation of neuroendocrine, but not of anti-craving effects. Neuropsychopharmacology
13. Shaham Y, Funk D, Erb S, Brown TJ, Walker CD, Stewart J. (1997). Corticotropin-releasing factor, but not corticosterone, is involved in stress-induced relapse to heroin-seeking in rats. J Neurosci 17: 2605-2614
14. Sinha R, Shaham Y, Heilig M. (2011). Translational and reverse translational research on the role of stress in drug craving and relapse. Psychopharmacology (Berl) 218: 69-82
15. Swanson LW, Sawchenko PE, Rivier J, Vale WW. (1983). Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 36: 165-186
16. Vale W, Spiess J, Rivier C, Rivier J. (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213: 1394-1397
17. Wikler A. (1952). A psychodynamic study of a patient during experimental self-regulated re-Addiction to morphine. Psychiatr Q 26: 270-293
18. Wray JM, Gass JC, Tiffany ST. (2013). A systematic review of the relationships between craving and smoking cessation. Nicotine Tob Res 15: 1167-1182
19. Zorrilla EP, Heilig M, De Wit H, Shaham Y. (2013). Behavioral, biological, and chemical perspectives on targeting CRF(1) receptor antagonists to treat alcoholism. Drug Alcohol Depend 128: 175-186